FDA advisers narrowly back accelerated approval of Sarepta gene therapy
May 12, 2023 at 19:13 PM EDT
FDA advisers vote 8-6 Friday to recommend the agency grant accelerated approval to Sarepta Therapeutics Inc.’s gene therapy for Duchenne muscular dystrophy.